UzbekistanTuberculosis profile
Population  2014 29 million
Estimates of TB burden * 2014 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 2.7 (2.3–3.1) 9.1 (8–10)
Mortality (HIV+TB only) 0.16 (0.12–0.2) 0.54 (0.42–0.69)
Prevalence  (includes HIV+TB) 36 (18–60) 122 (61–204)
Incidence  (includes HIV+TB) 24 (18–31) 82 (61–107)
Incidence (HIV+TB only) 0.83 (0.61–1.1) 2.8 (2.1–3.6)
         
Case detection, all forms (%) 76 (58–100)    
Estimates of MDR-TB burden * 2014   New   Retreatment
% of TB cases with MDR-TB 23 (18–29) 62 (52–71)
MDR-TB cases among notified pulmonary
TB cases
2 500 (1 900–3 100) 4 600 (3 900–5 200)
TB case notifications 2014 New ** Relapse
Pulmonary, bacteriologically confirmed 4 404   1 809
Pulmonary, clinically diagnosed 6 261   1 092
Extrapulmonary 4 514   265
       
Total new and relapse 18 345    
Previously treated, excluding relapses 4 459    
Total cases notified 22 804    
Among 18 345 new and relapse cases:
1 913 (10%) cases aged under 15 years; male:female ratio: 1.4
Reported cases of RR-/MDR-TB 2014 New Retreatment Total **
Cases tested for RR-/MDR-TB 11 956 (271%) 5 888 (77%) 17 988
Laboratory-confirmed RR-/MDR-TB cases     3 844
Patients started on MDR-TB treatment ***     3 665
TB/HIV 2014 Number (%)
TB patients with known HIV status 22 347 (98)
HIV-positive TB patients 780 (3)
HIV-positive TB patients on co-trimoxazole preventive therapy (CPT) 615 (79)
HIV-positive TB patients on antiretroviral therapy (ART) 354 (45)
HIV-positive people screened for TB 780  
HIV-positive people provided with IPT 2 438  
Treatment success rate and cohort size (%) Cohort
New and relapse cases registered in 2013 (83) 17 373
Previously treated cases, excluding relapse, registered in 2013 (78) 4 340
HIV-positive TB cases, all types, registered in 2013    
RR-/MDR-TB cases started on second-line treatment in 2012 (49) 1 491
XDR-TB cases started on second-line treatment in 2012 (14) 21
Laboratories 2014  
Smear (per 100 000 population) 1.1
Culture (per 5 million population) 1.2
Drug susceptibility testing (per 5 million population) 0.3
Sites performing Xpert MTB/RIF 24
Is second-line drug susceptibility testing available? Yes, in country
Financing TB control 2015  
National TB programme budget (US$ millions) 101
% Funded domestically 86%
% Funded internationally 14%
% Unfunded 0%
* Ranges represent uncertainty intervals
** Includes cases with unknown previous TB treatment history
*** Includes patients diagnosed before 2014 and patients who were not laboratory-confirmed as having
RR-/MDR-TB
***
(Rate per 100 000 population per year)
Mortality graph
   Mortality  (excludes HIV+TB)

(Rate per 100 000 population)
Prevalence graph
   Prevalence

(Rate per 100 000 population per year)
Incidence graph
   Notified (new and relapse)   Incidence
   Incidence (HIV+TB only)

(Number of patients)
CPT ART graph
   HIV-positive TB patients
   on CPT   on ART

Treatment success rate (%)
tx success graph
   New   Retreatment
   New and relapse   Retreatment, excluding
relapse
   HIV-positive   RR-/MDR-TB   XDR-TB

Total budget (US$ millions)
Budget funding Graph
__Funded domestically__Funded internationally
__Unfunded
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 Generated: 2016-05-06 Data: www.who.int/tb/data